Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 33,767,000 $ 77,404,000
Accounts receivable - trade 1,004,000 426,000
Settlement receivable - current portion 5,100,000 5,100,000
Investments in debt securities 14,813,000 19,570,000
Inventory 3,283,000 27,000
Prepaid expenses and other current assets 2,349,000 2,070,000
Total Current Assets 60,316,000 104,597,000
Restricted cash 5,941,000 0
Convertible promissory note receivable and accrued interest 1,612,000 1,556,000
Settlement receivable - noncurrent portion 0 5,100,000
Finance lease right-of-use assets, net of accumulated amortization 86,000 26,111,000
Operating lease right-of-use asset 5,151,000 0
Fixed assets, net of accumulated depreciation 34,581,000 8,628,000
Intangible assets, net of accumulated amortization 4,919,000 952,000
Investments in equity security - at cost 1,760,000 0
Prepaid expenses - noncurrent 975,000 0
Security deposits 29,000 24,000
Total Assets 115,370,000 146,968,000
Current liabilities:    
Accounts payable 5,279,000 2,254,000
Accrued expenses (related party of $0 and $701 as of March 31, 2022, and June 30, 2021, respectively) 2,939,000 3,001,000
Finance lease obligations - current portion 45,000 367,000
Operating lease obligation - current portion 10,000 0
Note payable - PPP loan - current portion 0 600,000
Contract liabilities 8,000 423,000
Total Current Liabilities 8,281,000 6,645,000
Finance lease obligations - net of current portion 41,000 31,755,000
Operating lease obligation - net of current portion 5,548,000 0
Term note payable - net of deferred financing costs 22,120,000 0
Total Liabilities 35,990,000 38,400,000
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized at March 31, 2022, and June 30, 2021; 218,165,624 and 217,873,094 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively 218,000 217,000
Additional paid-in capital 286,232,000 282,058,000
Accumulated other comprehensive loss (194,000) (63,000)
Accumulated deficit (206,876,000) (173,627,000)
Total iBio, Inc. Stockholders' Equity 79,380,000 108,585,000
Noncontrolling interest 0 (17,000)
Total Equity 79,380,000 108,568,000
Total Liabilities and Equity $ 115,370,000 $ 146,968,000